Research Shows People with Cancer, Heart Disease, Other Serious
Conditions Forced to Pay 10 Times More Than Necessary for
The Lund Report
July 11, 2013 -- Oregonians with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs, according to a report released today by the Oregon State Public Interest Research Group (OSPIRG) and Community Catalyst.
The report, “Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers,” reveals that these drugs were subject to an industry practice called “pay for delay,” in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay higher brand-name drug prices.